Paper Details

  1. Home
  2. Paper Details

Combined HPV 16 E2 and L1 methylation predict response to treatment with cidofovir and imiquimod in patients with vulval intraepithelial neoplasia.

Author: Alvarez-MendozaCarlos, HurtChristopher Nicholas, JonesSadie, NedjaiBelinda, PowellNed, TristramAmanda

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Topical cidofovir and imiquimod are effective treatments for vulval intraepithelial neoplasia (VIN) in approximately 55% of patients, avoiding the need for surgery. Human papillomavirus (HPV) E⁢2 gene methylation can predict response to treatment, but it can only be measured in approximately 50% of patients.
Paper Details　
Original Abstract of the Article :
Topical cidofovir and imiquimod can effectively treat approximately 55% of patients with vulval intraepithelial neoplasia (VIN), thus avoiding the need for surgery. Human papillomavirus (HPV) E⁢2 gene methylation predicts response to treatment but a methylation measurement is only obtainable in appr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661315/

データ提供：米国国立医学図書館（NLM）

HPV Methylation: A New Compass for Vulval Intraepithelial Neoplasia Treatment

Vulval intraepithelial neoplasia (VIN) is a precancerous condition that can be challenging to treat. This study investigates the potential of using human papillomavirus (HPV) methylation as a predictor of treatment response to cidofovir and imiquimod, two topical medications used to treat VIN.

HPV Methylation: A Potential Biomarker for Treatment Response

The study found that methylation of the HPV 16 E2 and L1 genes can predict treatment response to cidofovir and imiquimod. This discovery could be a valuable tool for guiding treatment decisions, allowing doctors to select the most appropriate therapy for each patient. Imagine a camel caravan using a compass to navigate the desert, with HPV methylation acting as a compass for choosing the right treatment path.

A Personalized Approach to VIN Treatment

This research suggests that HPV methylation could be used to personalize VIN treatment. By identifying patients who are likely to respond to cidofovir and imiquimod, doctors can optimize treatment outcomes and avoid unnecessary interventions. This is like using a detailed map to guide a camel caravan across a complex desert landscape, ensuring that the journey is efficient and successful.

Dr.Camel's Conclusion

This study offers promising insights into the use of HPV methylation as a predictive marker for treatment response in VIN. This discovery could lead to more personalized and effective treatment strategies, improving outcomes for patients. This research is like finding a hidden oasis in the desert, a source of hope and potential for a better future in the treatment of VIN.

Date :
  1. Date Completed 2022-10-25
  2. Date Revised 2022-11-29
Further Info :

Pubmed ID

35912731

DOI: Digital Object Identifier

PMC9661315

Related Literature

Article Analysis
・Effective treatment of hpv
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.